
CORRECTIONS

Journal Corrections

The February 10, 2011, review article by Pui et al, entitled, “Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update” (J Clin Oncol 29:551-565, 2011), contained errors.

In Figure 1A, the label for *CRLF2* overexpression was inadvertently misspelled as *CRFL2* overexpression.

In Figure 1A, under *MLL* rearrangements, t(4;22) was given as an example, whereas it should have been t(4;11).

Journal of Clinical Oncology apologizes for the mistakes.

DOI: 10.1200/JCO.2011.40.8245

The September 20, 2011, review article by Seruga and Tannock, entitled, “Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer” (J Clin Oncol 29:3686-3694, 2011), contained errors.

In the Introduction, the dosage for docetaxel was incorrectly given as once per week for three weeks in the second to last sentence of the fourth paragraph, whereas it should have been once every three weeks, as follows:

“Recent experience has shown that even in large centers with considerable experience, elderly patients with mCRPC treated with **docetaxel once every 3 weeks** may experience substantial toxicity with neutropenic fever, diarrhea, and dehydration.¹⁷”

In the section entitled “Evaluation of New Agents Following Progression During or After Docetaxel Treatment,” under subsection “Cabazitaxel and Other Agents That Stabilize Mi-

cro tubules,” the hazard ratio for cabazitaxel was given in the second sentence of the second paragraph as HR, 0.72, whereas it should have been HR, 0.70 as follows: “Cabazitaxel led to significantly better OS for men who received cabazitaxel (**HR, 0.70**; median OS, 15.1 v 12.7 months; $P < .001$).¹⁴”

Also in the same subsection, the dosage for cabazitaxel was incorrectly given in the first sentence of the fifth paragraph as 25 mg/m² three times per week, whereas it should have been 25 mg/m² every three weeks as follows:

“The dose of cabazitaxel administered in the TROPIC trial (**25 mg/m² every 3 weeks**) is not supported by the results of two early-phase clinical trials.”

The online version has been corrected in departure from the print. *Journal of Clinical Oncology* apologizes for the mistakes.

DOI: 10.1200/JCO.2011.40.8252

The October 20, 2011, article by Hendricks, Loggers, and Talcott, entitled, “Costs of Home Versus Inpatient Treatment for Fever and Neutropenia: Analysis of a Multi-center Randomized Trial” (J Clin Oncol 29:3984-3989, 2011), contained errors.

In Table 2, a footnote was indicated in the last column heading and should not have been called out.

In Table 3, under Home Treatment, an ^a footnote was called out for the mean charge for direct hospital costs, whereas as it should have been the * footnote, indicating “ $P < .01$ for home arm compared with hospital arm of study.”

Journal of Clinical Oncology apologizes for the mistakes.

DOI: 10.1200/JCO.2011.40.8260

The November 1, 2011, article by Polley et al, entitled, “Conditional Probability of Survival in Patients With Newly Diagnosed Glioblastoma” (J Clin Oncol 29:4175-4180, 2011) contained errors.

Appendix Tables A1 and A2 were inadvertently omitted from the online version.

In the Results section, under Patient Characteristics, Appendix Table A1 was inadvertently referenced as a Data Supplement in the first sentence.

In the Results section, under Overall Survival, Appendix Table A2 was inadvertently referenced as a Data Supplement in the first sentence.

The online version has been corrected in departure from the print. *Journal of Clinical Oncology* apologizes for the mistakes.

DOI: 10.1200/JCO.2011.40.8278
